TABLE 3

Details and Alternative Endpoints of Impact of PET on Intended Management by Cancer Type*

Change in management detailsChange in treatment goalsChange in treatment modes
Cancer typeNontreatment to treatmentTreatment to nontreatmentOdds ratioChange in goal of original treatment planChange from treatment to supportive care or observationMajor change in type of treatment relative to plan before PETMinor change in type of treatment relative to plan before PET
Prostate25.39.74.312.913.78.512.1
Ovary34.27.23.112.519.26.419.2
Bladder29.98.04.015.713.89.126.7
Pancreas31.27.83.816.913.58.626.5
Stomach28.28.74.016.014.48.631.5
Small cell lung34.96.33.913.913.27.428.6
Kidney27.78.13.812.620.79.719.2
Uterus28.97.64.413.815.99.827.4
Myeloma41.77.02.211.720.35.39.7
Connective tissue29.76.74.912.411.810.129.0
Nonmelanoma skin25.55.97.710.08.95.131.7
Liver and intrahepatic bile ducts33.69.22.618.210.814.723.7
Cervix25.47.35.913.513.87.434.7
Gallbladder31.58.23.517.812.610.422.1
Other female genital30.07.14.515.17.38.334.5
Thyroid26.49.23.814.716.111.526.0
All other27.69.03.714.520.08.922.6
Total30.08.03.914.115.18.623.3
  • * Specific cancer types are listed when there were at least 500 cases for initial staging, restaging, and detection of suspected recurrence combined.

  • Odds ratios compare chance of having plan for treatment after PET with chance of having plan for treatment before PET. Because more participants had treatment plans after PET than before PET, values were consistently higher than one.

  • Except for odds ratios, data are reported as percentages of cases.